{"id":"NCT02016716","sponsor":"Amgen","briefTitle":"A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis","officialTitle":"A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-03","primaryCompletion":"2014-09-08","completion":"2014-12-08","firstPosted":"2013-12-20","resultsPosted":"2018-11-08","lastUpdate":"2018-11-08"},"enrollment":294,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"Romosozumab 90 mg/mL","otherNames":["AMG 785","EVENITY™"]},{"type":"DRUG","name":"Placebo 90 mg/mL","otherNames":[]},{"type":"DRUG","name":"Romosozumab 70 mg/mL","otherNames":["AMG 785","EVENITY™"]},{"type":"DRUG","name":"Placebo 70 mg/mL","otherNames":[]}],"arms":[{"label":"Romosozumab 90 mg/mL","type":"EXPERIMENTAL"},{"label":"Placebo 90 mg/mL","type":"EXPERIMENTAL"},{"label":"Romosozumab 70 mg/mL","type":"EXPERIMENTAL"},{"label":"Placebo 70 mg/mL","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone mineral density (BMD) in postmenopausal women with osteoporosis.","primaryOutcome":{"measure":"Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine","timeFrame":"Baseline and month 6","effectByArm":[{"arm":"Placebo","deltaMin":0.8,"sd":null},{"arm":"Romosozumab 70 mg/mL","deltaMin":9.6,"sd":null},{"arm":"Romosozumab 90 mg/mL","deltaMin":9.2,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":9},"locations":{"siteCount":12,"countries":["United States","Czechia","Poland"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":26},"commonTop":["Nasopharyngitis","Asthenia","Injection site pain","Injection site erythema","Urinary tract infection"]}}